Press Releases - Supernus Pharmaceuticals

Date	Title
August 19, 2024	Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA	PDF Version
August 6, 2024	Supernus Announces Second Quarter 2024 Financial Results	PDF Version
August 1, 2024	Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device	PDF Version
July 23, 2024	Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024	PDF Version
May 30, 2024	Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference	PDF Version
May 23, 2024	Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy	PDF Version
May 9, 2024	Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures	PDF Version
May 8, 2024	Supernus Announces First Quarter 2024 Financial Results	PDF Version
May 1, 2024	Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story	PDF Version
April 24, 2024	Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024	PDF Version